29 results about "Heart tissues" patented technology

A catheter system for use with a catheter with a distal assembly supporting a plurality of electrodes adapted to sense electrical signal in heart tissue and a force sensor configured to generate first contact signals representative of a contact force acting on the distal assembly. The system includes an ablation power generator configured to energize the plurality of electrodes, an impedance circuitry configured to generate second contact signals representative of the electrodes in contact with tissue, a processor configured to receive the first and second contact signals and generate switch signals in response thereto, and a switch circuitry configured to connect in response to the switch signals solely selected electrodes in contact with tissue to the ablation power generator in forming one or more composite electrodes.

A transapical removal device that can be deployed in a catheter procedure to capture for removal or alteration a mitral valve clip or heart tissue, such as the anterior leaflet of the mitral valve, and methods of use are disclosed. The removal device includes a delivery catheter configured to be deployed near a mitral valve using a guide catheter. The delivery catheter has a snare head at the distal end, which assumes a collapsed state during movement of the delivery catheter through the guide catheter and deployed state for capturing a mitral valve clip or anterior leaflet. The snare head has one or more ablation delivery catheters configured to ablate tissue surrounding the pre-positioned mitral valve clip or anterior leaflet. In some arrangements within the scope of the present disclosure, the removal device includes a deployment mechanism for deploying a new transcatheter valve into the mitral valve.

A catheter utilizes a distal electrode array configured for quantification of endocardial or epicardial propagation velocity, with electrodes defining approximately equilateral triangles, such that the calculated velocity can be approximated regardless of the wave front direction. The distal electrode array can also include resilient splines carrying the electrodes such that the splines can deform to ensure contact between the electrodes and the heart tissue. Additionally, the electrodes of the distal electrode array can be individually addressable. Bipolar ablation lines or boxes can also be implemented using two parallel catheters at the endocardium and at the epicardium. Certain configurations include one or more distal electrode arrays of sufficient size to span an entire ventricular tachycardia (VT) circuit. The catheter may also be configured to detect block lines by pacing from edge pacing electrodes of the distal electrode array, and / or to detect fiber orientation by pacing from several edge pacing electrodes.

This invention relates to the field of biomedical technology, specifically to the application of PTPRM in the treatment and / or prevention of septic cardiomyopathy. This application found that the expression level of PTPRM was significantly reduced in the cardiac tissue of a CLP model, and further verified that overexpression of PTPRM significantly improved the survival rate of the CLP model. Furthermore, the reduction in PAT caused by CLP modeling, as well as the increases in RVDFW, RVSFW, LVSFW, LVDFW, IVS-s, and IVS-d, were also improved. In addition, overexpression of PTPRM can also reduce the expression level of cardiac troponin (cTNT) and right ventricular wall thickness. Therefore, PTPRM can be used as a target for the treatment of septic cardiomyopathy.

The invention relates to a lead device that comprises a lead tip with a distal fixation helix for fixing the lead tip at a patient's tissue (e.g., cardiac tissue, in particular tissue of the septum) wherein the fixation helix comprises a cutting portion for cutting the tissue in a circumferential direction of the fixation helix, in addition to a puncturing by a distal tip of the fixation helix (30), when the fixation helix is screwed into the tissue, to support longitudinal insertion of the lead tip with the fixation helix into the tissue. Thereby, insertion and longitudinal advancement of the lead tip into the tissue can be facilitated and smoothened due to a pre-cutting of the tissue in a circumferential direction at and / or around and / or within the fixation helix during the screwing operation into the tissue.

The application relates to application of miRNA and / or a miRNA agonist in preparation of a medicine for preventing and / or treating myocardial ischemia-reperfusion injury, and belongs to the technical field of biological medicine. The medicine is administered through skeletal muscle injection, is secreted to a circulation system after expression on the skeletal muscle, is delivered to heart tissue by taking extracellular vesicles as carriers, and thus regulates myocardial cell functions. According to the animal model verification result, the miRNA can be delivered to the heart by the extracellular vesicles secreted by the skeletal muscle through injection of the medicine into the skeletal muscle, the expression level of the miRNA in the I / RI heart is significantly increased, the myocardial infarction area is effectively reduced, myocardial cell apoptosis is inhibited, myocardial fibrosis is reduced, and heart function is improved, a brand-new intervention strategy is provided for treatment of myocardial ischemia-reperfusion injury and related heart diseases, and a brand-new idea is opened up for research and development of heart failure treatment medicines.

The invention relates to cellular microcompartments, each microcompartment successively comprising the following layers, which are organised around at least one lumen: —at least one inner layer of human cells undergoing cardiac differentiation, expressing at least one gene chosen from PDGFRα, MESP-1, NKX2-5, GATA4, MEF2C, TBX20, ISL1 and TBX5, —at least one intermediate layer of isotonic aqueous solution, and—at least one outer hydrogel layer. The invention also relates to the cardiac tissues obtained from said microcompartments and the use thereof, particularly in the treatment of heart disease.

This invention discloses a mouse experimental method for detecting the tissue distribution of exogenous oxytocin, belonging to the field of biotechnology. Specifically, oxytocin is injected into or nasally sprayed into oxytocin knockout mice, and body tissues, including but not limited to brain tissue, mammary gland tissue, blood, heart tissue, uterine tissue, bone tissue, and muscle tissue, are collected at different time points. The tissue distribution and content of oxytocin are then detected using liquid chromatography-mass spectrometry (LC-MS / MS). This experimental method allows for a wider range of experimental samples, not just focusing on brain tissue and blood; it also has higher sensitivity and stronger specificity; and by utilizing oxytocin gene knockout mice, it eliminates the influence of endogenous oxytocin, providing certain assistance for subsequent animal experiments and clinical research on oxytocin.

This invention relates to the field of biomedical technology. It provides a cardiac-targeting bispecific antibody protein and its applications. The bispecific antibody protein comprises a targeting conjugate that specifically recognizes NPR1 and a sequence that specifically recognizes GDF15. The amino acid sequence of the bispecific antibody protein is shown in SEQ ID NO.2. This invention cleverly achieves the dual functions of cardiac tissue targeting and effectively mediating endocytosis by utilizing a membrane protein specifically highly expressed in myocardial tissue as an effector molecule. The cardiac-targeting bispecific antibody protein of this invention can target the cardiac tissue surface receptor NPR1 and specifically target and degrade GDF15 within cardiac tissue, showing promising application prospects in the treatment of heart failure.

The application relates to a paravalvular leakage plugging device applied to a prosthetic valve with an annular body, comprising biodegradable foam attached to at least a section of the outer periphery of the annular body, which is water-swellable and has a first degradation rate; and a film wrapping the biodegradable foam, which is configured as a porous film and has a second degradation rate; when the biodegradable foam swells upon contact with water, the film does not constrain the swelling of the biodegradable foam, and the first degradation rate is different from the second degradation rate. The paravalvular leakage plugging device adopts biodegradable foam to plug the leakage, compared with a traditional metal plugging device, does not cause damage to the heart tissue and the valve, reduces the risk of complications, and meanwhile, the biodegradable foam gradually degrades after completing plugging, so that no residues are left in the human body, further reducing the long-term risk.

This invention relates to the fields of enzyme engineering and bioactive peptide preparation technology, and discloses a method for preparing equine cardiac muscle peptides with antioxidant and antithrombotic effects, comprising the following steps: S1: Pre-treating equine heart tissue to obtain equine cardiac muscle plasma; S2: Compound enzymatic hydrolysis and directing agent regulation: Adding a compound enzyme system and an antithrombotic directing agent to the equine cardiac muscle plasma; S3: Affinity chromatography enrichment. This invention constructs a synergistic process of compound enzymatic hydrolysis, directing regulation, and affinity enrichment, specifically addressing the technical problems of incomplete tissue fragmentation, low enzymatic hydrolysis efficiency, insufficient yield of active peptides, and easy oxidative inactivation in equine cardiac muscle due to the high proportion of type IIa myofibrous fibers and dense connective tissue. Furthermore, it employs a specific ratio of compound enzyme system adapted to the characteristics of equine cardiac muscle, significantly improving enzymatic hydrolysis efficiency; introduces a cationic directing agent to directionally increase the proportion of antithrombotic peptides generated; and combines thrombin affinity chromatography to achieve efficient enrichment of target peptides, significantly enhancing antithrombotic function while ensuring high antioxidant activity.

The application provides a heart tissue closure device. The device comprises a first clamping arm, a second clamping arm and an elastic member. One end of the first clamping arm is rotatably connected to one end of the second clamping arm, and the elastic member provides clamping force for the first clamping arm and the second clamping arm. The heart tissue closure device of the application provides clamping force through the elastic member, which is applied to the outside of the first clamping arm and the second clamping arm, so as to drive the clamping arms to flatten the inside auricle, realize the closure of the auricle, and prevent the auricle from being folded during ligation. The device can continuously provide stable clamping force through the elastic member, so as to ensure that the auricle can be completely closed when the thickness of the auricle is reduced. The device is wrapped by multiple layers, the contact area is increased, and the risk of tearing the heart tissue during clamping is prevented.

The single-fixing valve repairer comprises a clamping part and a flow blocking block, wherein the clamping part comprises a first clamping arm and a second clamping arm with elasticity for clamping a heart valve; the flow blocking block comprises a support and a flow blocking film, the flow blocking film is fixed by the support and connected to the clamping part, and bulges to one side to form a flow blocking part, so that the flow blocking film hides an implant interface arranged on the clamping part. The repairer can effectively reduce the stimulation of the exposed implant interface to the heart tissue and improve the treatment effect of the heart regurgitation surgery. The application further provides a heart valve repair system.

The application relates to the field of biological medicine, and provides an application of kaempferol or a Huaqinjiequ Decoction containing the same in the preparation of a jellyfish stinging treatment drug. The protection effect and mechanism of the Huaqinjiequ Decoction (HLJDT) on heart injury induced by Stomolophus meleagris venom (TE) are explored through in-vivo and in-vitro experiments. The results show that the HLJDT can significantly improve the cell survival rate and the survival rate of mice under TE exposure, reduce the abnormality of myocardial enzyme spectrum indexes, relieve the over-activation of the MAPK pathway and the expression of inflammatory factors, and improve the pathological injury of heart tissue. In combination with in-vivo and in-vitro activity evaluation, molecular docking and molecular mechanism research, it is further shown that kaempferol can effectively antagonize the myocardial cell toxicity caused by TE, and the mechanism is related to the inhibition of the MAPK signal axis. In summary, kaempferol is an important material basis for the Huaqinjiequ Decoction to antagonize inflammatory response and oxidative damage. It also plays an important role in reducing the myocardial cell toxicity and overall toxic effect induced by TE, and provides an experimental basis for preventing and treating jellyfish stings by using the traditional Chinese medicine compound modified HLJDT.

The application discloses a use of an active ingredient in repairing heart tissue damage. Specifically, the application discloses an active ingredient which can be used for repairing heart tissue damage and treating diseases related to lymphatic vessel abnormalities, and the active ingredient comprises a TBX1 protein, a coding sequence of the TBX1 protein, or a promoter of the TBX1 protein, or a combination thereof. The TBX1 protein can promote the proliferation of heart lymphatic vessel endothelial cells, play an immune regulation role, promote the establishment of an immune inhibition microenvironment in myocardium after heart tissue damage, inhibit an autoimmune reaction after the heart tissue damage, relieve concurrent heart tissue inflammation, and promote the repair and regeneration of the damaged heart tissue.

This invention provides a cardiac tissue closure device. The cardiac tissue closure device includes a first clamping arm, a second clamping arm, and an elastic portion. The first clamping arm includes a first inner arm and a first outer arm disposed opposite to each other, connected by a first elastic member. The second clamping arm includes a second inner arm and a second outer arm disposed opposite to each other, connected by a second elastic member. One end of the first clamping arm is rotatably connected to one end of the second clamping arm. The elastic portion provides clamping force to the first and second clamping arms. The cardiac tissue closure device of this invention provides clamping force through the elastic portion. This clamping force is applied to the outer sides of the first and second clamping arms, thereby driving the clamping arms to flatten the inner atrial appendage, achieving closure of the atrial appendage. This prevents folding gaps caused by ligation of the atrial appendage and avoids the risk of residual blood flow.

The application provides a heart tissue closure device. The heart tissue closure device comprises a first clamping arm, a second clamping arm and an elastic part. The first clamping arm comprises a first inner arm and a first outer arm arranged oppositely, and the first inner arm and the first outer arm are connected by a first elastic member. The second clamping arm comprises a second inner arm and a second outer arm arranged oppositely, and the second inner arm and the second outer arm are connected by a second elastic member. One end of the first clamping arm is rotationally connected with one end of the second clamping arm. The elastic part provides a clamping force for the first clamping arm and the second clamping arm. The heart tissue closure device provides a clamping force through the elastic part, and the clamping force is applied to the outer side of the first clamping arm and the second clamping arm, so as to drive the clamping arm to flatten the inner side of the auricle, realize the closure of the auricle, prevent the folding gap caused by the ligation of the auricle, and avoid the risk of residual blood flow.

Existing clinically adopted epicardial pacing leads mostly rely on surgical suturing or insertion of electrodes to the heart tissue. However, these approaches can cause tissue trauma during application and / or retrieval of the implants, potentially causing detrimental complications such as bleeding, tissue damage, and / or device failure. The present invention reports a bioadhesive epicardial pacing lead for atraumatic epicardial monitoring and stimulation of the heart in vivo to overcome the limitations of existing bioelectronic implants. The bioadhesive pacing lead is composed of an insulation layer, a conductive bioadhesive interface, a built-in reservoir, an electrode lead wire, and a fluidic channel. The bioadhesive pacing lead shows robust mechanical and electrical properties, biocompatibility, continuous epicardial monitoring and pacing capability, and rapid on-demand atraumatic employment and removal.

A catheter system for use with a catheter has a distal assembly and a force sensor. The distal assembly supports a plurality of electrodes adapted to sense electrical signals in cardiac tissue. The force sensor is configured to generate a first contact signal representing a contact force acting on the distal assembly. The system includes: an ablation power generator configured to energize the plurality of electrodes; an impedance circuit configured to generate a second contact signal representing an electrode in contact with tissue; a processor configured to receive the first and second contact signals and, in response, generate a switching signal; and a switching circuit configured to, in response to the switching signal, connect only selected electrodes in contact with tissue to the ablation power generator to form one or more composite electrodes.

The utility model discloses a kind of cardiac pacemaker lead wires, comprising: conductive transmission module, it includes conductor, the outer surface of the conductor is covered with insulating layer, two ends of the conductor are respectively fixed with two electrode heads, one of the electrode heads is used to contact with cardiac tissue, realize the perception and stimulation of electrical signal, limiting fixed module, it includes the corrugated sleeve and sleeve assembly of sliding sleeve in the conductor exterior, the sleeve assembly is fixedly connected with multiple evenly distributed oblique barbs.This utility model can hook pericardium of surrounding tissue by oblique barb, thereby preventing conductor from displacement, when pulling out conductor, only need to rotate conductor to make oblique barb not hook pericardium, can be smoothly extracted, by corrugated sleeve, sleeve assembly can be allowed to move moderately, make electrode head always keep good contact with cardiac tissue, and reduce the damage caused by oblique barb to endocardium in pulling process.

The invention provides a transferrin receptor (TfR1) antibody for conjugation to therapeutic payloads. The TfR1 antibodies may be used for delivering the therapeutic payloads, for instance oligonucleotide-based agents, to CNS tissues, skeletal muscle tissues, or heart tissues in vivo.

The invention is entitled "Measuring thickness of heart wall tissue during ablation". The invention discloses a method for estimating the thickness of heart tissue undergoing ablation, the method comprising the steps of: (a) applying a sequence of ablation pulses to a region of the heart tissue so as to produce an ablation lesion, and (b) for a given ablation pulse in the sequence, estimating an incremental depth added to the ablation lesion as a result of the given ablation pulse. A cumulative depth of the ablation lesion is estimated based on the cumulative depth prior to the given pulse and based on the incremental depth. An amplitude of an electrogram signal at the region is assessed after application of the given ablation pulse, and if the amplitude exceeds a predetermined threshold, the estimate of the thickness is set to at least the cumulative depth.

An implant removal device having an elongate body having a proximal end and a distal end, the elongate body being resiliently flexible and configured to transmit torque from the proximal end to the distal end with a predetermined turning ratio, and a capturing structure extending distally from the distal end and having a capture region, the capturing structure being configured to selectively center a deployed implant in relation to a longitudinal axis of the elongate body and the capture region to aid with capture and subsequent removal.

This invention relates to the field of medical surgical instruments, specifically to a flexible multi-channel cardiac mapping electrode for cardiac transport and its construction method. The mapping electrode includes a flexible substrate, multiple electrodes, and an encapsulation layer. The flexible substrate has multiple branches, with the fixed ends of all branches connected to a common part. Multiple electrode arrays are disposed on the side of each branch that contacts the heart for measuring the cardiac potential. The flexible substrate is made of a biocompatible flexible insulating material, allowing each branch to be adsorbed by the surface tension of the body fluid on the outer surface of the heart. This not only reduces stimulation and damage to cardiac tissue but also allows the electrodes to more precisely conform to the heart surface, accurately measuring the cardiac potential and greatly improving the accuracy of cardiac electrical activity mapping.

This invention discloses a method comprising locating a Koch triangle region in the right atrium of a patient's heart; securing at least one electrode of an implantable lead or device from the Koch triangle region to cardiac tissue for delivery of atrium-to-ventricle (VfA) cardiac therapy; and testing the position or depth of the at least one electrode to configure the VfA cardiac therapy. Locating the target implantation area in the Koch triangle region may include detecting atrial slow path potentials (ASP) or atrial pacing outputs.

The application discloses a preparation method and application of an autologous mitochondrion preparation, relates to the technical field of kidney protection and regeneration, and is characterized in that the mitochondrion is derived from heart tissue of a healthy C57 mouse of 8-10 weeks old, is obtained through a kit combined with a differential centrifugation method, and is characterized in that the obtained mitochondrion is continuous in outer membrane and clear in ridge structure under an electron microscope, and has good structural and functional integrity. In an in-vivo experiment, the mitochondrion is delivered to the renal cortex region of a recipient mouse through a subcapsular injection method 30 minutes before ischemia-reperfusion, and the result shows that the blood creatinine and urea nitrogen levels can be significantly reduced, the necrosis and oxidative stress damage of renal tubular epithelial cells can be reduced, and the renal tissue pathological score can be improved. The application provides a repeatable and standardizable organelle treatment strategy for intervention of kidney transplantation and acute kidney injury related IRI.

A catheter system for use with a catheter with a distal assembly supporting a plurality of electrodes adapted to sense electrical signal in heart tissue and a force sensor configured to generate first contact signals representative of a contact force acting on the distal assembly. The system includes an ablation power generator configured to energize the plurality of electrodes, an impedance circuitry configured to generate second contact signals representative of the electrodes in contact with tissue, a processor configured to receive the first and second contact signals and generate switch signals in response thereto, and a switch circuitry configured to connect in response to the switch signals solely selected electrodes in contact with tissue to the ablation power generator in forming one or more composite electrodes.

This invention discloses a method for extracting interstitial fluid from cardiac tissue, belonging to the field of biomedical technology. Based on the unique characteristics of the heart, a organ closely related to blood circulation, and its differences in tissue physical properties compared to other organs, this invention designs and develops this extraction method, which specifically includes: rinsing isolated cardiac tissue with pre-cooled physiological saline; low-speed centrifugation to remove residual rinsing fluid from the heart; and centrifugation again to obtain interstitial fluid from the cardiac tissue. Comparison of the obtained interstitial fluid with cardiac cell fluid and serum confirms the accuracy and specificity of the extraction scheme of this invention. The centrifugation process of this invention does not damage cells, preserving its unique differences from serum and cardiac cell fluid. The extracted interstitial fluid has a high protein concentration, which can better reflect changes in the cardiac microenvironment, facilitating subsequent related medical and basic research.

The present invention provides VFA delivery and implant region detection. A method is disclosed that includes locating a Koch triangle region in a right atrium of a patient's heart; securing at least one electrode of an implantable lead or device to heart tissue from the Koch triangle region to deliver atrium-to-ventricle (VfA) cardiac therapy; and testing a location or depth of the at least one electrode to configure the VfA cardiac therapy. Locating a target implant region in the Koch triangle region can include detecting an atrial slow pathway potential (ASP) or an atrial pacing output.